Adherence to HIV Treatment as Prevention and Preexposure Prophylaxis

Amico, K. Rivet

doi:10.1007/978-1-4614-8845-3_5

Cited by 2 publications

(3 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In CASI and interviews, facilitators for taking pills included developing habits, such as keeping pills visible, and a commitment to HIV research and to the study. The impact on adherence of developing habits and using reminder tools is well described in the ART (and other) adherence literature , and further underscored by our findings. These results highlight the importance of verifying patients’ understanding about the timing of medications and what to do when doses are inadvertently missed or taken late.…”

Section: Discussionmentioning

confidence: 99%

Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions

et al. 2019

View full text Add to dashboard Cite

Introduction Limited data exist on acceptability of candidate pre‐exposure prophylaxis (PrEP) regimens among US women. We evaluated PrEP experiences, attitudes and future use intentions among sexually active women who completed the US‐based HIV Prevention Trials Network 069/AIDS Clinical Trials Group 5305 study. Methods Women participated in the study between March 2013 and November 2015. We analysed computer‐assisted self‐interview (CASI) surveys among 130 women and conducted in‐depth interviews among a subset of 26 women from three sites. Interviews were conducted in mid/late‐2015. Results Most women (57%) reported very good/excellent PrEP adherence on CASI, although 21% acknowledged over‐reporting adherence at least some of the time. Commitment to preventing HIV infection, a sense of ownership of the study, and keeping pills stored in a visible location facilitated adherence. Adherence barriers included “simply forgetting” and being away from home. Most women interviewed did not intend to use PrEP in the future because of lack of perceived need due to their own (as opposed to their partners’) low‐risk behaviour and concerns about affordability – but not because of side effects or other characteristics of the regimens. Conclusions Improving HIV prevention options for US women will require access to affordable PrEP as well as expanding women's understanding of relationship‐ and community‐level factors that increase their risk of acquiring HIV.

show abstract

Section: Discussionmentioning

confidence: 99%

Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Consistent with Centers for Disease Control and Prevention and World Health Organization clinical guidelines [42–45], all demonstration projects have some form of adherence education and/or counseling, which have been characterized loosely into community-level, technology-based (eg, texting, mobile apps, websites), monitoring-based (eg, providing information about drug detection, intensification of intervention based on drug detection), and integrated prevention strategies [8]. Integrated sexual health promotion counseling [46] and comprehensive care [47], where the focus is on personalized prevention plans and overall health, rather than adoption of and adherence to a single prevention strategy (eg, PrEP), is an innovative approach unique to open-label PrEP projects.…”

Section: Supporting Prep Adherencementioning

confidence: 99%

“…The last several years has witnessed a surge of research addressing preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV), and a number of reviews are available [ 1 – 8 ]. The focus of this review is to provide the current evidence base for PrEP adherence with a specific emphasis on current knowledge and remaining gaps, highlighting the areas for improvement and contribution from sociobehavioral science.…”

mentioning

confidence: 99%

Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence

Amico

Stirratt

2014

Clinical Infectious Diseases

Self Cite

115

View full text Add to dashboard Cite

Despite considerable discussion and debate about adherence to preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV), scant data are available that characterize patterns of adherence to open-label PrEP. The current evidence base is instead dominated by research on adherence to placebo-controlled investigational drug by way of drug detection in active-arm participants of large randomized controlled trials (RCTs). Important differences between the context of blinded RCTs and open-label use suggest caution when generalizing from study product adherence to real-world PrEP use. Evidence specific to open-label PrEP adherence is presently sparse but will expand rapidly over the next few years as roll-out, demonstration projects, and more rigorous research collect and present findings. The current evidence bases established cannot yet predict uptake, adherence, or persistence with open-label effective PrEP. Emerging evidence suggests that some cohorts could execute better adherence in open-label use vs placebo-controlled research. Uptake of PrEP is presently slow in the United States; whether this changes as grassroots and community efforts increase awareness of PrEP as an effective HIV prevention option remains to be determined. As recommended by multiple guidelines for PrEP use, all current demonstration projects offer PrEP education and/or counseling. PrEP support approaches generally fall into community-based, technology, monitoring, and integrated sexual health promotion approaches. Developing and implementing research that moves beyond simple correlates of either study product use or open-label PrEP adherence toward more comprehensive models of sociobehavioral and socioecological adherence determinants would greatly accelerate progress. Intervention research is needed to identify effective models of support for open-label PrEP adherence.

show abstract

Adherence to HIV Treatment as Prevention and Preexposure Prophylaxis

Cited by 2 publications

References 89 publications

Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions

Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions

Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence

Contact Info

Product

Resources

About